ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: ALXN1007
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2014-03-31
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01883544
- Locations
- 🇺🇸
PAREXEL Baltimore EPCU, Baltimore, Maryland, United States
Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-05-08
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01849562
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Completed
- Conditions
- Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2013-01-18
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01770951
The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2012-12-31
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01757431
- Locations
- 🇯🇵
Nagano Red Cross Hospital, Nagano, Japan
🇯🇵Tokyo Medical and Dental University Hospital, Tokyo, Japan
Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency
Phase 3
Completed
- Conditions
- Lysosomal Acid Lipase Deficiency
- Interventions
- Drug: PlaceboDrug: Sebelipase Alfa
- First Posted Date
- 2012-12-28
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT01757184
To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients
Completed
- Conditions
- ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2012-12-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01755429
- Locations
- 🇯🇵
Tokyo Medical and Dental University, Tokyo, Japan
🇯🇵Shinshu University School of Medicine, Matsumoto, Japan
Evaluation of Safety, Tolerability, and Antiviral Activity of ACH-0143102 Plus Ribavirin In Treatment-naive Hepatitis C Virus Infection Genotype 1b Participants
Phase 1
Completed
- Conditions
- Chronic Hepatitis C Infection
- Interventions
- Drug: ACH-0143102Drug: Ribavirin
- First Posted Date
- 2012-10-04
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT01700179
Lysosomal Acid Lipase (LAL) Deficiency Registry
Recruiting
- Conditions
- Cholesterol Ester Storage DiseaseWolman DiseaseAcid Lipase DeficiencyLysosomal Acid Lipase DeficiencyAcid Cholesteryl Ester Hydrolase Deficiency, Type 2LIPA DeficiencyLAL-Deficiency
- First Posted Date
- 2012-07-04
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT01633489
Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor
- First Posted Date
- 2012-03-30
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT01567085
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
Completed
- Conditions
- Cholesterol Ester Storage Disease(CESD)Lysosomal Acid Lipase Deficiency
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01528917
- Locations
- 🇺🇸
Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath